Press Releases

BrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 29, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing innovative biomarker data from the NurOwn® Phase 2 randomized double-blind placebo-controlled study will be presented at the 28th International Symposium on ALS/MND, to take place December 8-10 in Boston, MA.

Logo - hi-res

The posters will feature the analyses of chitotriosidase (CHIT-1) and microRNAs (miRNAs) in the cerebrospinal fluid (CSF) of ALS patients participating in the Phase 2 study, as biomarkers to evaluate ALS disease progression and NurOwn® treatment response.

"Our Phase 2 placebo-controlled trial demonstrated clinical activity for NurOwn® in ALS, including evidence of disease halting, and the data in these two abstracts support the mechanism of action of NurOwn®.  We are pleased to have them accepted for poster presentation at the prestigious ALS/MND symposium, which is the largest medical and scientific conference specific to MND/ALS.  We are committed to advancing ALS science and to the development of innovative and advanced cell therapies to meaningfully address neurological diseases," commented BrainStorm's CEO Chaim Lebovits.

Presentation details are as follows:


Chitotriosidase as a biomarker for ALS


Friday December 8, 2017


17.45 – 19.30, Eastern Time


Poster Session A


Modulation of miRNAs in the CSF of ALS patients treated with MSC-NTF cells



Saturday December 9, 2017


17.45 – 19.30, Eastern Time


Poster Session B

The 28th International Symposium on ALS/MND will take place at the Westin Boston Waterfront, 425 Summer Street, Boston. For more information, refer to 

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 70 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the company's website at

Safe-Harbor Statement  

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.


Uri Yablonka
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188

Michael Rice
LifeSci Advisors LLC
Phone: 646-597-6979

Matt Middleman, M.D.
LifeSci Public Relations, LLC
Phone: 646-627-8384

View original content with multimedia:

SOURCE BrainStorm Cell Therapeutics Inc.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds